Literature DB >> 6691968

Selective inhibition of thrombin by (2R,4R)-4-methyl-1-[N2-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl++ +) sulfonyl]-l-arginyl)]-2-piperidinecarboxylic acid.

R Kikumoto, Y Tamao, T Tezuka, S Tonomura, H Hara, K Ninomiya, A Hijikata, S Okamoto.   

Abstract

The potency of thrombin inhibition by 4-methyl-1-[N2-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl)-sulfony l]- L-arginyl]-2-piperidinecarboxylic acid (MQPA) depended on the stereoconformation of the 2-piperidinecarboxylic acid moiety. Ki values for bovine alpha-thrombin were 0.019 microM with (2R,4R)-MQPA, 0.24 microM with (2R,4S)-MQPA, 1.9 microM with (2S,4R)-MQPA, and 280 microM with (2S,4S)-MQPA. (2R,4R)-MQPA of the four stereoisomers of MQPA was also the most potent inhibitor for other trypsin-like serine proteases with Ki values of 5.0 microM for trypsin, 210 microM for factor Xa, 800 microM for plasmin, and 1500 microM for plasma kallikrein. Examination of the potency of thrombin inhibition by arginine derivatives related to MQPA in structure suggested the presence of a specific binding site for the carboxamide portion (C-terminal side). The relative inhibitory potency of the four stereoisomers of MQPA for trypsin was nearly identical with that for thrombin, suggesting that the specific binding site for the carboxamide portion is present in both enzymes. Modification of thrombin by phosphopyridoxylation or the presence of heparin did not significantly alter the binding of MQPA.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6691968     DOI: 10.1021/bi00296a014

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  28 in total

1.  A model for the binding of low molecular weight inhibitors to the active site of thrombin.

Authors:  M C Allen; X L Cockcroft; M G Gruetter; J P Priestle
Journal:  J Comput Aided Mol Des       Date:  1999-11       Impact factor: 3.686

Review 2.  Tissue Engineering at the Blood-Contacting Surface: A Review of Challenges and Strategies in Vascular Graft Development.

Authors:  Daniel Radke; Wenkai Jia; Dhavan Sharma; Kemin Fena; Guifang Wang; Jeremy Goldman; Feng Zhao
Journal:  Adv Healthc Mater       Date:  2018-05-07       Impact factor: 9.933

Review 3.  Prediction of binding constants of protein ligands: a fast method for the prioritization of hits obtained from de novo design or 3D database search programs.

Authors:  H J Böhm
Journal:  J Comput Aided Mol Des       Date:  1998-07       Impact factor: 3.686

4.  Development of microporous self-expanding stent grafts for treating cerebral aneurysms: designing micropores to control intimal hyperplasia.

Authors:  Shogo Nishi; Yasuhide Nakayama; Hatsue Ishibashi-Ueda; Yoshihiro Okamoto; Masato Yoshida
Journal:  J Artif Organs       Date:  2011-06-23       Impact factor: 1.731

5.  Functionality map analysis of the active site cleft of human thrombin.

Authors:  P D Grootenhuis; M Karplus
Journal:  J Comput Aided Mol Des       Date:  1996-02       Impact factor: 3.686

6.  Combined argatroban and anti-oxidative agents prevents increased vascular contractility to thrombin and other ligands after subarachnoid haemorrhage.

Authors:  Katsuharu Kameda; Yuichiro Kikkawa; Mayumi Hirano; Satoshi Matsuo; Tomio Sasaki; Katsuya Hirano
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

7.  Evidence for common structural changes in thrombin induced by active-site or exosite binding.

Authors:  M A Parry; S R Stone; J Hofsteenge; M P Jackman
Journal:  Biochem J       Date:  1993-03-15       Impact factor: 3.857

Review 8.  Novel antithrombotic drugs in development.

Authors:  M Verstraete; P Zoldhelyi
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

9.  Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury.

Authors:  J F Eidt; P Allison; S Noble; J Ashton; P Golino; J McNatt; L M Buja; J T Willerson
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

10.  Molecular basis for the inhibition of human alpha-thrombin by the macrocyclic peptide cyclotheonamide A.

Authors:  B E Maryanoff; X Qiu; K P Padmanabhan; A Tulinsky; H R Almond; P Andrade-Gordon; M N Greco; J A Kauffman; K C Nicolaou; A Liu
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.